ClinicalTrials.gov
ClinicalTrials.gov Menu

Axicabtagene Ciloleucel Expanded Access Study (ZUMA-9)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03153462
Expanded Access Status : Available
First Posted : May 15, 2017
Last Update Posted : September 27, 2018
Sponsor:
Information provided by (Responsible Party):
Kite, A Gilead Company

May 11, 2017
May 15, 2017
September 27, 2018
 
Axicabtagene Ciloleucel Expanded Access Study
A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma.
Not Provided
Expanded Access
Treatment IND/Protocol
Biological: Axicabtagene Ciloleucel
Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Available
Contact: Medical Information 844-454-KITE medinfo@kitepharma.com
United States
 
 
NCT03153462
Kite, A Gilead Company
Kite, A Gilead Company
Not Provided
Study Director: Kite Study Director Kite, A Gilead Company
Kite, A Gilead Company
September 2018